Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Monte Rosa Therapeutics (GLUE) Research & Development (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Research & Development data on record, last reported at $36.7 million in Q3 2025.

  • For Q3 2025, Research & Development rose 32.81% year-over-year to $36.7 million; the TTM value through Sep 2025 reached $138.4 million, up 26.0%, while the annual FY2024 figure was $121.6 million, 9.25% up from the prior year.
  • Research & Development reached $36.7 million in Q3 2025 per GLUE's latest filing, up from $30.7 million in the prior quarter.
  • Across five years, Research & Development topped out at $38.9 million in Q4 2024 and bottomed at $26.8 million in Q1 2023.
  • Average Research & Development over 3 years is $30.2 million, with a median of $28.3 million recorded in 2023.
  • The widest YoY moves for Research & Development: up 43.23% in 2024, down 3.51% in 2024.
  • A 3-year view of Research & Development shows it stood at $27.1 million in 2023, then soared by 43.23% to $38.9 million in 2024, then fell by 5.63% to $36.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $36.7 million in Q3 2025, $30.7 million in Q2 2025, and $32.2 million in Q1 2025.